Search Clinical Trials
Sponsor Condition of Interest |
---|
Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog
Mayo Clinic
Long COVID
This study aims to assess the effects of both acute and chronic exposures to hypoxia and
hypercapnia in patients with Long COVID syndrome. expand
This study aims to assess the effects of both acute and chronic exposures to hypoxia and hypercapnia in patients with Long COVID syndrome. Type: Interventional Start Date: Sep 2024 |
A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.
Pfizer
COVID-19
The purpose of the study is to learn about:
- how PF-07817883 is processed in the body of adult participants.
- the safety of PF-07817883.
These participants will have different levels of kidney function loss:
- moderate
- severe
- none or healthy Participants with moderate,... expand
The purpose of the study is to learn about: - how PF-07817883 is processed in the body of adult participants. - the safety of PF-07817883. These participants will have different levels of kidney function loss: - moderate - severe - none or healthy Participants with moderate, severe or no loss of kidney function may be taken into one of 3 groups. This study is seeking for participants who: - are male or female of 18 to 90 years of age. - have different levels of damage to kidney function or for one of the groups, no damage - are willing to follow the requirements of the study including stay at clinic for 5 nights and 6 days. About, 8 participants may be selected in groups 2 and 3. In group 1, around 8 to 12 participants may be selected. If participants agree to take part in the study, it may take up to 4 weeks to complete all the tests to confirm if they are fit to be in the study. If they seem to be fit for the study, participants will be admitted to a clinic research unit (CRU) at least 8 hours before dosing. On Day 1, participants will receive a single amount of study medicine (Day 1). A series of blood samples will be collected before and after giving medicines. Participants will be discharged from the CRU on Day 5. A follow-up phone call (or CRU visit, if needed), will occur 28-35 days after taking the medicine. The whole study will last for a minimum of 5 weeks and a maximum of 10 weeks. Type: Interventional Start Date: Sep 2024 |
A Study to Investigate the Immunogenicity of mRNA COVID-19 Variant-containing Vaccine Formulations in...
ModernaTX, Inc.
SARS-CoV-2
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19
variant-containing vaccine formulations against the vaccine matched variants and newly
emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in
previously vaccinated adults. expand
The purpose of this study is to investigate the immunogenicity of mRNA COVID-19 variant-containing vaccine formulations against the vaccine matched variants and newly emerged variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in previously vaccinated adults. Type: Interventional Start Date: Sep 2024 |
Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID
Mayo Clinic
Long COVID
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut
microbiome diversity of long-COVID subjects. expand
The purpose of this study is to evaluate the effects of fermented foods on bacterial gut microbiome diversity of long-COVID subjects. Type: Interventional Start Date: Sep 2024 |
Improving Attention in Individuals With Long COVID-19
Shirley Ryan AbilityLab
Long Covid
This study is to find out if the Attention Processing Training program is a potential
treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating
the feasibility of completing this program virtually. expand
This study is to find out if the Attention Processing Training program is a potential treatment for brain fog symptoms, reported by people with Long-Covid. Also investigating the feasibility of completing this program virtually. Type: Interventional Start Date: Mar 2024 |
Wearable Assisted Viral Evidence (WAVE) Study A Decentralized, Prospective Study Exploring the Relationship...
Evidation Health
Influenza, Human
COVID-19
Influenza A
Influenza B
Respiratory Syncytial Virus (RSV)
The goal of this decentralized, observational study is to enroll and observe adults in
the contingent United States during the 2023-2024 flu season. The main study objectives
are to create a dataset of paired wearable data, self-reported symptoms, and respiratory
viral infection (RVI) from PCR testing... expand
The goal of this decentralized, observational study is to enroll and observe adults in the contingent United States during the 2023-2024 flu season. The main study objectives are to create a dataset of paired wearable data, self-reported symptoms, and respiratory viral infection (RVI) from PCR testing during the 2023-2024 flu season and to develop algorithm that is able to accurately classify asymptomatic and symptomatic RVI and understand the algorithm's performance metrics. Type: Observational Start Date: Jan 2024 |
A Study to Learn About New COVD-19 RNA Vaccine Candidates for New Variants in Healthy Individuals
BioNTech SE
SARS-CoV-2 Infection
COVID-19
The purpose of this clinical protocol is to learn about the safety, tolerability, and
immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of
SARS-CoV-2 in healthy people.
Substudy A:
- This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2... expand
The purpose of this clinical protocol is to learn about the safety, tolerability, and immunogenicity of new BNT162b2 RNA-based vaccine candidates targeting new variants of SARS-CoV-2 in healthy people. Substudy A: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who previously received at least 3 doses of a US-authorized mRNA COVID-19 vaccine, with the most recent dose being an Omicron BA.4/BA.5-adapted bivalent vaccine received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy B: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi XBB.1.5) given as a single 30 µg dose, - in people who are 12 years of age and older, - who are COVID-19 vaccine-naïve - who have had any positive SARS-CoV-2 test result >28 days before study vaccine administration. - The study is about 6 months long for each participant. - Participants will have at least 5 visits to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Substudy C: - This study will evaluate the safety, tolerability, and immunogenicity of BNT162b2 (Omi JN.1) and BNT162b2 (Omi KP.2) given as a single 30 µg dose to: - Cohort 1: people who are 18 years of age and older, who will receive BNT162b2 (Omi JN.1), and, - Cohort 2: people who are 12 years of age and older, who will receive BNT162b2 (Omi JN.1), and, - Cohort 3: people who are 18 years of age and older who will receive BNT162b2 (Omi KP.2). - Participants may have never received a COVID-19 vaccine or, may have previously received COVID-19 vaccine(s), with the most recent dose received at least 150 days before the study vaccination (Visit 1). - The study is about 6 months long for each participant. - Participants will have at least 6 visits (Cohorts 1 and 3) or at least 5 visits (Cohort 2) to the clinic. - At each clinic visit a blood sample will be taken. - At least 1 nasal swab will taken. Type: Interventional Start Date: Aug 2023 |
Strategies and Treatments for Respiratory Infections &Amp; Viral Emergencies (STRIVE): Immune Modulation...
University of Minnesota
COVID-19
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that
immune modulation can improve outcomes in hospitalized patients. This trial is designed
to determine whether intensification of immune modulation early in the course of the
disease (while patients are on low... expand
COVID-19 can trigger a dysregulated immune response, and previous studies have shown that immune modulation can improve outcomes in hospitalized patients. This trial is designed to determine whether intensification of immune modulation early in the course of the disease (while patients are on low flow oxygen) with abatacept (active arm) combined with standard of care (SOC) improves recovery as compared with placebo + SOC (placebo arm). For both groups, intensification of immunomodulation will be provided as part of SOC in case of signs of disease progression (patient requires high flow nasal oxygen (HFNO) or more support) and/or if the patient has rapidly increasing oxygen requirement. Type: Interventional Start Date: Jul 2023 |
A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms...
Pfizer
SARS-CoV-2 Infection
The purpose of the study is to understand the effects and safety of PF-07817883
treatment. The study wants to know how PF-07817883 treatment lowers the level of the
virus that causes COVID 19. To understand that samples are collected from adult
participants who have the symptoms of COVID 19 but are... expand
The purpose of the study is to understand the effects and safety of PF-07817883 treatment. The study wants to know how PF-07817883 treatment lowers the level of the virus that causes COVID 19. To understand that samples are collected from adult participants who have the symptoms of COVID 19 but are not hospitalized. The study is seeking for participants who: - are 18 years of age or older at the time of entering the study. - have a positive rapid antigen test within 48 hours before entering the study. Rapid antigen test is a test done to confirm the presence of a specific virus in the body. - have onset of signs or symptoms of COVID-19 within 5 days before entering the study. - have at least 1 of the specified signs or symptoms of COVID-19 present on the day of entering the study. Around 228 participants with a confirmed case of COVID 19 are planned to be taken into the study. Participants will be randomly grouped to receive PF-07817883. Three groups will receive 100, 300, 600mg of PF-07817883 and one of the groups will receive placebo (a pill that doesn't have any medicines) orally every 12 hours for 5 days. The study is going to last up to 5 weeks. This includes the initial period of selecting participants, participants receiving the medicine or the placebo and then a 4-week follow-up period after giving the participants the last medicine. The study team will monitor how each participant is doing with the study treatment during the study. Type: Interventional Start Date: May 2023 |
Immune Registry for Organ Transplantation From COVID Positive Donors.
Virginia Commonwealth University
COVID-19
Organ Transplant
The purpose of this study is to collect data generated by standard clinical practice to
determine the short term and long term clinical outcomes of recipients of solid organ
transplantation from COVID-19 infected donors and compare it to recipients with organ
transplant from COVID-19 negative donors. expand
The purpose of this study is to collect data generated by standard clinical practice to determine the short term and long term clinical outcomes of recipients of solid organ transplantation from COVID-19 infected donors and compare it to recipients with organ transplant from COVID-19 negative donors. Type: Observational [Patient Registry] Start Date: Dec 2022 |
Baby2Home (B2H) Mobile Health Application
Women and Infants Hospital of Rhode Island
COVID-19 Pandemic
Health Knowledge, Attitudes, Practice
Perinatal Depression
Mental Health Wellness
Post Partum Depression
The COVID-19 pandemic has transformed healthcare delivery; arguably, the fields of
obstetrics and pediatrics have experienced some of the greatest changes as they have
transitioned away from their role as a medical home and into more of an urgent care model
of care. Baby2Home is a digital health intervention... expand
The COVID-19 pandemic has transformed healthcare delivery; arguably, the fields of obstetrics and pediatrics have experienced some of the greatest changes as they have transitioned away from their role as a medical home and into more of an urgent care model of care. Baby2Home is a digital health intervention designed to bridge the resultant gaps in obstetrics and pediatrics healthcare services for new families over the first year of life. This randomized controlled trial will evaluate whether, compared to usual care, Baby2Home 1) improves maternal, paternal, and infant health service utilization outcomes over the first year postpartum, 2) improves maternal and paternal patient reported outcomes, and 3) reduces racial/ethnic and income-based disparities in preventive health services utilization and parental patient reported outcomes. Type: Interventional Start Date: Nov 2022 |
A Study to Learn About a Repeat 5-Day Treatment With the Study Medicines (Called Nirmatrelvir/Ritonavir)...
Pfizer
COVID-19
The purpose of this study is to learn about the safety and effects of
nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound.
The study is seeking participants who:
- Have completed treatment with nirmatrelvir/ritonavir
- Have a rebound in COVID-19 symptoms
- Are... expand
The purpose of this study is to learn about the safety and effects of nirmatrelvir/ritonavir for the potential treatment of COVID-19 rebound. The study is seeking participants who: - Have completed treatment with nirmatrelvir/ritonavir - Have a rebound in COVID-19 symptoms - Are SARS-CoV-2 (COVID-19) positive All study medications will be taken 2 times a day by mouth for 5 days. The first dose of study medication is taken at the study clinic and the rest at home. We will examine the experiences of people receiving the study medicines to those who do not. This will help us determine if the study medicines are safe and effective. People taking part will be in this study for about 24 weeks. Enrolled participants will need to visit the study clinic at least 8 times during the study. Type: Interventional Start Date: Oct 2022 |
A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older...
Pfizer
COVID-19
The purpose of this clinical trial is to learn about the safety and effects of the study
medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19.
Patients with COVID-19 who have more difficulty in fighting against infections have a
higher chance of severe illness. Such patients... expand
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called Nirmatrelvir/Ritonavir) for the possible treatment of COVID-19. Patients with COVID-19 who have more difficulty in fighting against infections have a higher chance of severe illness. Such patients may benefit from longer treatment durations compared to the standard treatment regimen. The study is seeking participants who: - Have a confirmed COVID-19 infection - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 5 days prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. In addition, this study will also evaluate the efficacy and safety of a second treatment course of nirmatrelvir/ritonavir in people who experience that their COVID-19 is flaring up within 14 days of having taken a 5-day treatment course of nirmatrelvir/ritonavir. For this group, the study is seeking participants who: - Have a confirmed COVID-19 infection - Experience a worsening of signs/symptoms after completing an initial 5-day course of nirmatrelvir/ritonavir - The worsening of COVID-19 symptoms must occur within 14 days after completion of the initial 5-day course of nirmatrelvir/ritonavir - Are Immunocompromised - Experience onset of signs/symptoms attributable to the current COVID-19 infection within 48 hours prior to screening and ≥1 signs/symptoms attributable to COVID-19 present on the day of randomization. All participants will be taking the study medicine for either 5, 10, or 15 days. The study medication will be taken by mouth 2 times a day. Participants will take part in this study for about 24 weeks. The first dose of study medication is taken at the study site and the rest at home. Selected participants will need to visit the study site at least 10 times during the study. Type: Interventional Start Date: Aug 2022 |
IMM-BCP-01 in Mild to Moderate COVID-19
Immunome, Inc.
SARS-CoV2 Infection
COVID-19
The primary objective of this study is to evaluate the safety and tolerability of
intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28.
The secondary objectives of the study are to:
- Determine pharmacokinetics (PK) and evaluate viral clearance after single... expand
The primary objective of this study is to evaluate the safety and tolerability of intravenous (IV) IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. The secondary objectives of the study are to: - Determine pharmacokinetics (PK) and evaluate viral clearance after single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Day 28. - Evaluate the safety and tolerability, determine PK, and evaluate viral clearance of single ascending doses of IV IMM-BCP-01 in subjects with mild to moderate COVID-19 through Week 12. Type: Interventional Start Date: Jun 2022 |
Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate...
Vitti Labs, LLC
COVID-19 Acute Respiratory Distress Syndrome
Respiratory Distress Syndrome
Recent advances have been made in prevention of the viral infection via vaccines but
there is still need for effective treatment options for patients. Novel therapies need to
be developed to further improve clinical outcomes. The biggest medical challenge in the
response to COVID-19 is ARDS requiring... expand
Recent advances have been made in prevention of the viral infection via vaccines but there is still need for effective treatment options for patients. Novel therapies need to be developed to further improve clinical outcomes. The biggest medical challenge in the response to COVID-19 is ARDS requiring hospitalization in an intensive care setting and ventilator dependence. Intravenously administered umbilical cord derived exosomes and stem cells have been reported in literature to alleviate pulmonary distress in such patients. The purpose of this study is to explore the safety and benefits of intravenous administration of WJPure and EVPure in the treatment of COVID-19 patients with moderate to severe ARDS. . Type: Interventional Start Date: Mar 2025 |
Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology...
University Hospitals Cleveland Medical Center
Post-acute COVID-19 Syndrome
Participants are being asked to take part in this research study because they have had a
previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent,
recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The
Investigators are interested in studying... expand
Participants are being asked to take part in this research study because they have had a previous diagnosis (at least 3 months ago) of COVID-19 and are experiencing persistent, recurrent or even new symptoms, i.e. post-acute sequelae of SARS-CoV-2 (PASC). The Investigators are interested in studying the effects of Vitamin K2 (MK-7) and Vitamin D3 supplementation on PASC symptoms and the underlying inflammatory process. Type: Interventional Start Date: Jun 2022 |
In Utero Exposure to SARS-CoV-2 (COVID-19) and Cardiovascular and Metabolic Endpoints in Early Life
Massachusetts General Hospital
In Utero SARS-CoV-2 Exposure
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by
the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by
inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant
women have had a heightened prevalence... expand
Since its initial outbreak in late 2019, coronavirus disease 2019 (COVID-19) caused by the novel coronavirus SARS-CoV-2 has ravaged the globe, causing illness characterized by inflammation and impaired oxygen levels. As a particularly vulnerable group, pregnant women have had a heightened prevalence and severity of infection. In this context, a new population of children has emerged who were exposed to maternal COVID-19 in the womb. As maternal diseases during pregnancy may impact the health of offspring over the life course, health outcomes among these individuals must be urgently evaluated. In the current study, the investigators will leverage a perinatal biorepository comprised of pregnant women with and without COVID-19 to delineate the metabolic and cardiovascular risk profiles of these offspring. This work stands to benefit the burgeoning population of children exposed to COVID-19 in the womb and to deepen the mechanistic understanding of developmental origins of cardiometabolic disease with respect to maternal infections. Type: Observational Start Date: Jun 2021 |
Direct Topical Lung T3 Treatment to Improve Outcome & Sequelae of COVID-19 Acute Respiratory Distress...
University of Minnesota
Covid19
SARS-CoV Infection
ARDS
ARDS, Human
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients
on mechanical ventilation. expand
Acute treatment of COVID-ARDS with direct topical lung instilled T3 therapy for patients on mechanical ventilation. Type: Interventional Start Date: Jan 2025 |
Trial of Combination Therapy to Treat COVID-19 Infection
ProgenaBiome
COVID
Covid-19
Corona Virus Infection
Coronavirus Infection
Coronavirus-19
In this trial patients will be treated with either a combination of therapies to treat
COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6
months. expand
In this trial patients will be treated with either a combination of therapies to treat COVID-19 or a placebo. Treatment will last 10 days, and patients will be followed for 6 months. Type: Interventional Start Date: Dec 2020 |
A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection
ProgenaBiome
COVID-19
Coronavirus Infection
Sars-CoV2
Corona Virus Infection
COVID
This is a Phase II interventional study testing whether treatment with
hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19 expand
This is a Phase II interventional study testing whether treatment with hydroxychloroquine, Vitamin C, Vitamin D, and Zinc can prevent symptoms of COVID-19 Type: Interventional Start Date: Jun 2020 |
Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients
Novartis Pharmaceuticals
Sickle Cell Disease (SCD)
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate
dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years
with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The
efficacy and safety of crizanlizumab... expand
The purpose of the Phase 2 CSEG101B2201 study is to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 6 months to <18 years with a history of VOC with or without HU/HC, receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was already demonstrated in adults with sickle cell disease. The approach is to extrapolate from the PK/pharmacodynamics (PD) already established in the adult population. The study is designed as a Phase II, multicenter, open-label study. Type: Interventional Start Date: Oct 2018 |
COVID-19 Self-testing IMPROVE
Temple University
COVID-19
The study aims to engage community partners to implement IMPROVE intervention and promote
(COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia
Area and New York City expand
The study aims to engage community partners to implement IMPROVE intervention and promote (COVID-19) rapid testing among vulnerable Asian Americans in the Greater Philadelphia Area and New York City Type: Interventional Start Date: Jun 2023 |
Cardiopulmonary Exercise Tests in Patients With Long COVID
Sheffield Hallam University
Long COVID
COVID Long-Haul
The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings
has been established in the last decade. CPET methods remain highly relevant in the
COVID-19 endemic phase and should be used to assess those recovering from COVID-19
(SARS-CoV-2) infection. This diagnostic tool... expand
The value of clinical cardiopulmonary exercise testing (CPET) within healthcare settings has been established in the last decade. CPET methods remain highly relevant in the COVID-19 endemic phase and should be used to assess those recovering from COVID-19 (SARS-CoV-2) infection. This diagnostic tool could play an integral role in disease prognostication and evaluate the integrative response to incremental exercise. Date from such assessments can enable practitioners to characterise cardio-respiratory fitness and identify reasons for physical impairment or abnormal cardio-respiratory function. More than 50% of patients admitted to hospital will experience cardiorespiratory issues and significant morbidity during their recovery and will require significant rehabilitative support. In this context, measurements obtained from an assessment of cardio-respiratory responses to physiological stress could provide insight regarding the integrity of the pulmonary-vascular interface and characterisation of any impairment or abnormal cardio-respiratory function. Current approaches to rehabilitation are being developed on existing knowledge from Severe Acute Respiratory Syndrome (SARS) and Acute Respiratory Distress Syndrome (ARDS) related illness. These provide important insight but do not provide insight into the novel challenges provided by COVID-19. Type: Observational Start Date: Mar 2023 |
Xofluza-Wearables Feasibility-Study
Children's Hospital of Philadelphia
Infection, Coronavirus
Infections
Influenza
Transplant
Infection Viral
The goal of this prospective, interventional, single-center study is to assess whether
the early detection of Influenza with smartwatch algorithms and alerting, rapid testing,
and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus
publicly available- and Centers for Disease... expand
The goal of this prospective, interventional, single-center study is to assess whether the early detection of Influenza with smartwatch algorithms and alerting, rapid testing, and subsequent Baloxavir treatment demonstrate better post-infection outcomes versus publicly available- and Centers for Disease Control (CDC)-derived national statistics for equivalent household populations as well as pediatric kidney, heart, liver, lung transplant recipients and waitlisted patients. Type: Interventional Start Date: Dec 2023 |
RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long...
Duke University
Long COVID
Long Covid19
Long Covid-19
This platform protocol is designed to be flexible so that it is suitable for a wide range
of settings within health care systems, for remote settings, and in community settings
where it can be integrated into COVID-19 programs and subsequent treatment plans.
This protocol is a prospective, multi-center,... expand
This platform protocol is designed to be flexible so that it is suitable for a wide range of settings within health care systems, for remote settings, and in community settings where it can be integrated into COVID-19 programs and subsequent treatment plans. This protocol is a prospective, multi-center, multi-arm, randomized, controlled platform trial evaluating potential interventions for PASC-mediated cognitive dysfunction. The hypothesis is that PASC associated dysfunction in cognitive domains, such as executive function and attention, may be improved by interventions that selectively focus on enhancing those domains. Type: Interventional Start Date: Sep 2023 |
- Previous
- Next